

## AMENDMENTS

### Amendments in the claims:

Claims 1-9. (canceled).

Claim 10. (currently amended): A mutant *ras* peptide ~~having a size of~~ comprising:  
an amino acid sequence of at least 8 to no more than 13 amino acids, wherein said amino  
acid sequence compris[[ing]]es Xaa<sub>1</sub> Leu Xaa<sub>2</sub> Val Val Gly Ala Xaa<sub>3</sub> Gly Val (SEQ ID NO:14);  
wherein Xaa<sub>1</sub> is the amino acid lysine or tyrosine;  
wherein Xaa<sub>2</sub> is an amino acid;  
wherein Xaa<sub>3</sub> is selected from the group consisting of aspartic acid, valine,  
cysteine, alanine, arginine, [[and]] or serine;  
~~with the proviso that~~ wherein when Xaa<sub>2</sub> is valine, Xaa<sub>1</sub> is tyrosine  
and said peptide elicits a peptide-specific human CD8<sup>+</sup> cytotoxic T lymphocyte  
immune response.

Claim 11. (currently amended): The mutant *ras* peptide ~~according to~~ of claim 10, wherein  
the peptide comprises an amino acid sequence of 13 amino acids.

Claim 12. (currently amended): The mutant *ras* peptide ~~according to~~ of claim 10, wherein  
the peptide comprises an amino acid sequence of 10 amino acids.

Claim 13. (currently amended): The mutant *ras* peptide ~~according to~~ of claim 10, ~~11 or 12~~  
wherein Xaa<sub>1</sub> is tyrosine.

Claim 14. (currently amended): The mutant *ras* peptide ~~according to~~ of claim 10, ~~11, 12 or 13~~ wherein Xaa<sub>2</sub> is selected from the group consisting of valine, tryptophan, leucine, tyrosine, and phenylalanine.

Claim 15. (currently amended): The mutant *ras* peptide ~~according to~~ of claim 10, ~~11, 12, 13 or 14~~ wherein Xaa<sub>1</sub> is tyrosine, and Xaa<sub>3</sub> is aspartic acid.

Claims 16-24. (canceled).

Claim 25. (currently amended): A mutant *ras* peptide-carrier molecule conjugate comprising the mutant *ras* peptide ~~according to~~ of claim[[s]] 10-~~23 or 24~~ and a carrier molecule, wherein said carrier molecule enhances the immunogenicity of the peptide.

Claim 26. (canceled).

Claim 27. (currently amended): An immunogen for eliciting a mutant *ras* peptide-specific human CD8<sup>+</sup> cytotoxic T lymphocyte immune response comprising a mutant *ras* peptide ~~according to~~ of claim[[s]] 10-~~23 or 24 or combination thereof~~, wherein the immunogen elicits a mutant *ras* peptide-specific human CD8<sup>+</sup> cytotoxic T lymphocyte immune response.

Claims 28-31. (canceled).

Claim 32. (currently amended): A pharmaceutical composition comprising the mutant *ras* peptide of claim[[s]] 10[[-24]] and a pharmaceutically acceptable carrier.

Claim 33. (currently amended): The pharmaceutical composition ~~according to~~ of claim 32, further comprising a biological response modifier.

Claim 34. (currently amended): The pharmaceutical composition ~~according to~~ of claim[[s]] 32 ~~or 33~~, further comprising a liposome formulation, an antigen presenting cell, or an adjuvant comprising mycobacterial cell wall skeleton and monophosphoryl lipid A.

Claims 35-65. (canceled).

Claim 66. (currently amended): The mutant *ras* peptide-carrier molecule conjugate ~~according to~~ of claim 25, wherein the carrier molecule is selected from the group consisting of influenza peptide, tetanus toxoid-CD4 epitope, Pseudomonas exotoxin A<sub>1</sub> and poly-L-lysine.

Claim 67. (currently amended): The mutant *ras* peptide-carrier molecule conjugate ~~according to~~ of claim 25, wherein the carrier molecule is tetanus toxoid.

Claim 68. (currently amended): The pharmaceutical composition ~~according to~~ of claim 33, wherein the biological response modifier is interleukin 2.

Claim 69. (canceled).

Claim 70. (currently amended): The pharmaceutical composition ~~according to~~ of claim 32, further comprising interleukin 2, interleukin 6, interleukin 12, interferon, tumor necrosis factor, GM-CSF,  $\beta_2$ -microglobulin, or combinations thereof.

Claim 71. (new) The pharmaceutical composition of claim 33, further comprising a liposome formulation, an antigen presenting cell, or an adjuvant comprising mycobacterial cell wall skeleton and monophosphoryl lipid A.